Pyrotinib Combined With Trastuzumab and AI in the First-line Treatment of HER2 Positive/ HR Positive MBC
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer Female|HER2-positive Breast Cancer|Hormone Receptor Positive Malignant Neoplasm of Breast|Metastatic Breast Cancer|Breast Diseases|Hormone Receptor Positive Tumor
Interventions: DRUG: Pyrotinib|DRUG: Trastuzumab|DRUG: Aromatase inhibitor
Sponsor: Peking Union Medical College Hospital